Xenon Pharmaceuticals Inc
XP0
Company Profile
Business description
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Contact
200-3650 Gilmore Way
BurnabyBCV5G 4W8
CANT: +1 604 484-3300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
370
Stocks News & Analysis
stocks
Weight loss drugs not an existential threat to undervalued ASX share
A durable growth story despite GLP-1 headwinds.
stocks
Tesla: valuation is key consideration in merger talks with SpaceX
We see regulatory risk from both the US and Chinese governments.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,965.00 | 38.40 | 0.43% |
| CAC 40 | 7,847.32 | 64.50 | 0.83% |
| DAX 40 | 25,410.84 | 229.19 | 0.91% |
| Dow JONES (US) | 52,361.58 | 146.42 | 0.28% |
| FTSE 100 | 10,767.33 | 76.97 | 0.72% |
| HKSE | 23,183.93 | 27.88 | -0.12% |
| NASDAQ | 26,169.38 | 214.04 | 0.82% |
| Nikkei 225 | 63,489.43 | 1,299.78 | 2.09% |
| NZX 50 Index | 13,636.19 | 97.74 | -0.71% |
| S&P 500 | 7,676.77 | 53.09 | 0.70% |
| S&P/ASX 200 | 8,845.80 | 35.90 | 0.41% |
| SSE Composite Index | 3,692.58 | 4.94 | -0.13% |